Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kaixin Changyu Granule is a traditional Chinese medicine (TCM) formulation developed for the treatment of post-stroke depression. It is administered in granule form and used as an adjunct or alternative to conventional antidepressant therapies, particularly in patients recovering from stroke. The mechanism of action is not fully elucidated but, consistent with many TCM products for neuropsychiatric indications, it likely involves modulation of neurotransmitter systems and neuroprotective effects through multi-component herbal ingredients. The product is currently being studied in clinical trials to evaluate its efficacy and safety for post-stroke depression[8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Kaixin Changyu Granule.